20142523

Source:http://linkedlifedata.com/resource/pubmed/id/20142523

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0020179, umls-concept:C0034656, umls-concept:C0058188
pubmed:issue	2
pubmed:dateCreated	2010-2-9
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00497159
pubmed:abstractText	To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/R01 AG031189-04
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20142523
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0372436
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Indoles, http://linkedlifedata.com/resource/pubmed/chemical/dimebolin
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	1538-3687
pubmed:author	pubmed-author:Corey-BloomJodyJ, pubmed-author:DeuelLisa MLM, pubmed-author:Dimebon in Subjects with Huntington Disease (DIMOND) Investigators of..., pubmed-author:DorseyE RayER, pubmed-author:FactorStewartS, pubmed-author:FeiginAndrewA, pubmed-author:GeschwindMichael DMD, pubmed-author:HodgemanKarenK, pubmed-author:Huntington Disease Study Group DIMOND Investigators, pubmed-author:KaysonEliseE, pubmed-author:KieburtzKarlK, pubmed-author:McDermottMichael PMP, pubmed-author:NoonbergSarahS, pubmed-author:PourfarMichaelM, pubmed-author:RabinowitzKarenK, pubmed-author:RavinaBernardB, pubmed-author:Sanchez-RamosJuanJ, pubmed-author:SeelyLynnL, pubmed-author:VossTiffini STS, pubmed-author:WalkerFrancisF
pubmed:issnType	Electronic
pubmed:volume	67
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	154-60
pubmed:dateRevised	2011-6-17
pubmed:meshHeading	pubmed-meshheading:20142523-Adult, pubmed-meshheading:20142523-Aged, pubmed-meshheading:20142523-Antipsychotic Agents, pubmed-meshheading:20142523-Cognition, pubmed-meshheading:20142523-Double-Blind Method, pubmed-meshheading:20142523-Electrocardiography, pubmed-meshheading:20142523-Female, pubmed-meshheading:20142523-Humans, pubmed-meshheading:20142523-Huntington Disease, pubmed-meshheading:20142523-Indoles, pubmed-meshheading:20142523-Male, pubmed-meshheading:20142523-Mental Status Schedule, pubmed-meshheading:20142523-Middle Aged, pubmed-meshheading:20142523-Motor Activity, pubmed-meshheading:20142523-Neuropsychological Tests, pubmed-meshheading:20142523-Retrospective Studies, pubmed-meshheading:20142523-Time Factors, pubmed-meshheading:20142523-Treatment Outcome
pubmed:year	2010
pubmed:articleTitle	A randomized, placebo-controlled trial of latrepirdine in Huntington disease.
pubmed:affiliation	Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study